Lilly In Collaboration To Screen NIH Pharmaceuticals Collection, Make Pharmacology Data Public

Repurposing opportunities are unlikely in this NCATS/Lilly project, which has the loftier goal of furthering understanding of how small molecule drugs actually work in complex human systems in order to improve drug development for the entire “research universe.”

Lilly Research Laboratories will apply its Phenotypic Drug Discovery assays to 3,800 approved and investigational small molecule drugs from the National Institutes of Health’s collection of all known drugs approved for human use, with the goal of improving drug development by providing a better understanding of how drugs work in complex human systems. The project should take 12 to 18 months, and all data will be made public following the Human Genome Project model.

“If we’re going to get better at making drugs that do good things and don’t do bad things, then we...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By 

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.